Tenaya Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 140
- Market Cap
- $216.1M
- Introduction
Tenaya Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics for cardiovascular diseases. It operates through its product platforms: gene therapy, cellular regeneration, and precision medicine. The company was founded by Deepak Srivastava, Benoit G. Bruneau, Bruce R. Conklin, Sheng Ding, Saptarsi Haldar, and Eric Olson in 2016 and is headquartered in South San Francisco, CA.
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Tenaya Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT06311708
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Colorado, Denver, Aurora, Colorado, United States
🇺🇸John Hopkins University School of Medicine, Baltimore, Maryland, United States
Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC
- Conditions
- Arrhythmogenic Right Ventricular Cardiomyopathy
- Interventions
- Genetic: TN-401
- First Posted Date
- 2024-01-29
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- Tenaya Therapeutics
- Target Recruit Count
- 15
- Registration Number
- NCT06228924
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Genetic: TN-201
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Tenaya Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT05836259
- Locations
- 🇺🇸
The Christ Hospital Physicians - The Ohio Heart and Vascular Center, Cincinnati, Ohio, United States
🇺🇸UC San Diego Altman Clinical and Translational Research Institute - Center for Clinical Research, La Jolla, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
- Conditions
- Cardiomyopathy
- First Posted Date
- 2021-11-08
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Tenaya Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT05112237
- Locations
- 🇺🇸
Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
🇺🇸Children's Medical Center Dallas, Dallas, Texas, United States
🇺🇸Cleveland Clinic Main Campus, Cleveland, Ohio, United States